Clinical Trial

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-10-08; most recent amendment 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2020-01-28
Trial Details
NCT Number NCT04121468
Lead Sponsor The Hospital for Sick Children
Collaborators: Queen's University, Ontario Institute for Regenerative Medicine, Unity Health Toronto, Stem Cell Network, Multiple Sclerosis Society of Canada
Conditions Multiple Sclerosis (MS)
Enrollment 20 participants
Start Date 2020-02-24
Primary Completion 2027-03 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-23